OBI-3424, a Novel AKR1C3-activated Prodrug, Exhibits Potent Efficacy Against Preclinical Models of T-All
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-19-0551
Full Text
Open PDFAbstract
Available in full text
Date
April 23, 2019
Authors
Publisher
American Association for Cancer Research (AACR)